(Q33891629)

29 July 2017

1 reference

title

Combining sulfonylureas and other oral agents (English)

1 reference

29 July 2017

Riddle M

1

1 reference

PubMed ID

10764846

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

American Journal of Medicine

29 July 2017

1 reference

29 July 2017

108 Suppl 6a

1 reference

29 July 2017

15S-22S

1 reference

Tactics for type II diabetes

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Hyperglycemia and microvascular and macrovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900338-7

10.1016/S0002-9343(00)00338-7

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10764846